PDCD1 and colorectal carcinoma: Programmed cell death 1 (PD-1) antibodies, serving as immune checkpoint inhibitors (ICIs), have demonstrated notable therapeutic efficacy in patients exhibiting high microsatellite instability (MSI-H), a condition present in approximately 15% of all CRC cases [4].